Intellectual property and orphan drug designation
Vicore has during the last years built a strong position in ATRAG chemistry and has a platform of promising new molecules with patent protection to at least 2041 and beyond
under development.
Vicore has an active patent strategy encompassing all major geographic markets, including the U.S., Europe, Canada, Japan, and China. In addition to the granted original NCE patent for buloxibutid (C21), several patents are pending covering its formulations, manufacturing and use, with projected expiry 2040 and beyond.
Moreover, orphan drug status is granted for buloxibutid in IPF providing up to ten years protection in Europe and an up to seven years in the United States from the time of regulatory approval. Provided that Vicore receives market approval, NCE market exclusivity for buloxibutid in IPF will also be protected for ten years in Europe and five years in the US.
